- Home
- ATOS vs NIM Comparison
ATOS vs NIM Comparison
Compare ATOS & NIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATOS | NIM |
|---|---|---|
| Founded | 2009 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.8M | 115.7M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATOS | NIM |
|---|---|---|
| Price | $0.84 | $9.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.33 | N/A |
| AVG Volume (30 Days) | ★ 892.0K | 35.4K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.46% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $8.28 |
| 52 Week High | $1.29 | $9.74 |
Technical Indicators
Market Signals| Indicator | ATOS | NIM |
|---|---|---|
| Relative Strength Index (RSI) | 51.07 | 43.34 |
| Support Level | $0.68 | $9.23 |
| Resistance Level | $0.99 | $9.40 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 44.30 | 17.65 |
Price Performance
Historical ComparisonAbout ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About NIM Nuveen Select Maturities Municipal Fund
Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its primary investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital. Its secondary investment objective is to enhance portfolio value relative to the municipal bond market through investments in tax-exempt municipal obligations that are underrated or undervalued, or that represent municipal market sectors that are undervalued.